Autolus Therapeutics (NASDAQ:AUTL) Given "Buy" Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL - Free Report) in a research note released on Thursday morning,Benzinga reports. Needham & Company LLC currently has a $10.00 price objective on the stock.

Several other analysts also recently weighed in on the stock. Truist Financial cut their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Wells Fargo & Company cut their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 21st. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Autolus Therapeutics has a consensus rating of "Buy" and an average target price of $9.32.

Autolus Therapeutics Trading Down 4.0%

AUTL stock traded down $0.09 during mid-day trading on Thursday, hitting $2.15. 2,811,283 shares of the company were exchanged, compared to its average volume of 1,562,673. The company has a market capitalization of $572.20 million, a PE ratio of -1.78 and a beta of 1.76. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.00. The firm has a fifty day simple moving average of $1.53 and a 200 day simple moving average of $1.96.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The business had revenue of $8.98 million for the quarter, compared to the consensus estimate of $1.59 million. As a group, sell-side analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Several large investors have recently bought and sold shares of AUTL. Handelsbanken Fonder AB grew its stake in shares of Autolus Therapeutics by 30.9% in the 4th quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company's stock worth $172,000 after purchasing an additional 17,300 shares during the last quarter. HealthInvest Partners AB grew its stake in shares of Autolus Therapeutics by 8.4% in the 4th quarter. HealthInvest Partners AB now owns 479,644 shares of the company's stock worth $1,060,000 after purchasing an additional 37,221 shares during the last quarter. Candriam S.C.A. acquired a new position in shares of Autolus Therapeutics in the 4th quarter worth approximately $7,500,000. Daiwa Securities Group Inc. grew its stake in shares of Autolus Therapeutics by 55.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares during the last quarter. Finally, Privium Fund Management B.V. grew its stake in shares of Autolus Therapeutics by 24.8% in the 4th quarter. Privium Fund Management B.V. now owns 231,674 shares of the company's stock worth $544,000 after purchasing an additional 46,035 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.